LYON, France--(BUSINESS WIRE)--Flamel Technologies (NASDAQ:FLML) today announced its financial results for the fourth quarter and year ended December 31, 2006.
The major highlight of the fourth quarter was the approval by the FDA of the New Drug Application for COREG CR™. Once-a-day COREG CR is approved for three indications:
